Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Antisense Oligonucleotide Inhibition of Bcl-xL and Bid Expression in Liver Regulates Responses in a Mouse Model of Fas-Induced Fulminant Hepatitis

Hong Zhang, Jennifer Taylor, Doreen Luther, Joe Johnston, Susan Murray, Jacqueline R. Wyatt, Andrew T. Watt, Seongjoon Koo, Cathie York-DeFalco, Kimberly Stecker and Nicholas M. Dean
Journal of Pharmacology and Experimental Therapeutics October 2003, 307 (1) 24-33; DOI: https://doi.org/10.1124/jpet.103.050435
Hong Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Taylor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doreen Luther
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joe Johnston
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Murray
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline R. Wyatt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew T. Watt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seongjoon Koo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cathie York-DeFalco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly Stecker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas M. Dean
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Activation of the cell-surface receptor Fas can lead to apoptosis in parenchymal cells in the liver, and if severe enough, result in fulminant hepatic failure and animal death. In the present study, we have examined the roles played by the Bcl-2 family members Bcl-xL and Bid in regulating this response. To do this, we have developed chemically modified 2′-O-(2-methoxy) ethyl antisense inhibitors of both Bid and Bcl-xL expression. In Balb/c mice, dosing with these antisense oligonucleotides reduced expression of the targeted mRNA by greater than 80% in the liver. This reduction was highly dependent upon oligonucleotide sequence and oligonucleotide dose. Reduction of Bcl-xL expression resulted in a potentiation of Fas-mediated apoptosis in liver and significant increase of the lethality of Fas-mediated fulminant hepatitis (p < 0.0001). In contrast, reduction of Bid expression protected the animals against Fas-mediated fulminant hepatitis and death (p < 0.0001). Simultaneous dosing of mice with Bcl-xL and Bid-targeting antisense oligonucleotides resulted in an inhibition of expression of both targeted proteins and protection of the animals from Fas-mediated apoptosis. These results demonstrate, for the first time, the role of Bcl-xL in regulating responses to proapoptotic Fas signaling in mouse liver. In addition, this is the first reported example demonstrating the ability of antisense inhibitors to reduce expression of multiple proteins in animals by simultaneous dosing.

Footnotes

  • DOI: 10.1124/jpet.103.050435.

  • ABBREVIATIONS: 2′-O-MOE, 2′-O-(2-methoxy) ethyl; ALT, alanine aminotransferase.

    • Received February 12, 2003.
    • Accepted June 11, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 307 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 307, Issue 1
1 Oct 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antisense Oligonucleotide Inhibition of Bcl-xL and Bid Expression in Liver Regulates Responses in a Mouse Model of Fas-Induced Fulminant Hepatitis
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Antisense Oligonucleotide Inhibition of Bcl-xL and Bid Expression in Liver Regulates Responses in a Mouse Model of Fas-Induced Fulminant Hepatitis

Hong Zhang, Jennifer Taylor, Doreen Luther, Joe Johnston, Susan Murray, Jacqueline R. Wyatt, Andrew T. Watt, Seongjoon Koo, Cathie York-DeFalco, Kimberly Stecker and Nicholas M. Dean
Journal of Pharmacology and Experimental Therapeutics October 1, 2003, 307 (1) 24-33; DOI: https://doi.org/10.1124/jpet.103.050435

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Antisense Oligonucleotide Inhibition of Bcl-xL and Bid Expression in Liver Regulates Responses in a Mouse Model of Fas-Induced Fulminant Hepatitis

Hong Zhang, Jennifer Taylor, Doreen Luther, Joe Johnston, Susan Murray, Jacqueline R. Wyatt, Andrew T. Watt, Seongjoon Koo, Cathie York-DeFalco, Kimberly Stecker and Nicholas M. Dean
Journal of Pharmacology and Experimental Therapeutics October 1, 2003, 307 (1) 24-33; DOI: https://doi.org/10.1124/jpet.103.050435
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • GPER Activation Prevented the Development of Acute Colitis
  • RGD Engagement and Downregulation of αvβ6
  • LPA and Renal Disease
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics